Specific adverse events: gastrointestinal perforations or fistulae ‐ not reported · women with recurrent or FIGO stage IVB cervical cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Specific adverse events: haemorrhage · women with recurrent or FIGO stage IVB cervical cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Specific adverse events: thromboembolic events ‐ not reported · women with recurrent or FIGO stage IVB cervical cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events: hypertension · women with recurrent or FIGO stage IVB cervical cancer
Apatinib plus chemotherapy or chemotherapy/brachytherapy may leads to higher specific adverse events: hypertension compared with chemotherapy or chemotherapy/brachytherapy (low certainty).
1 finding from 1 review
Serious adverse events ‐ not reported · women with recurrent or FIGO stage IVB cervical cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Economic evaluation ‐ not measured · women with recurrent or FIGO stage IVB cervical cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
3‐year OS · patients with epithelial ovarian cancer
Platin‐based maintenance chemotherapy showed no clear difference in 3‐year OS compared with observation (moderate certainty).
1 finding from 1 review
5‐year OS · patients with epithelial ovarian cancer
Platin‐based maintenance chemotherapy showed no clear difference in 5‐year OS compared with observation (moderate certainty).
1 finding from 1 review
10‐year OS · patients with epithelial ovarian cancer
Platin‐based maintenance chemotherapy showed no clear difference in 10‐year OS compared with observation (moderate certainty).
1 finding from 1 review
Progression‐free survival · patients with epithelial ovarian cancer
Platin‐based maintenance chemotherapy showed no clear difference in 3‐year PFS compared with observation (moderate certainty).
3 findings from 1 review
RR 1.04 [0.86, 1.24]
3 studies · 341 participants
Moderate
RR 1.18 [0.88, 1.58]
2 studies · 219 participants
Moderate
RR 0.96 [0.65, 1.41]
2 studies · 219 participants
Moderate
Overall survival (OS) · newly‐diagnosed EOC
Chemotherapy with bevacizumab followed by maintenance bevacizumab showed no clear difference in overall survival (OS) compared with chemotherapy alone (moderate certainty).
1 finding from 1 review
Overall survival (OS) · platinum‐sensitive recurrent EOC
Chemotherapy with bevacizumab followed by bevacizumab maintenance showed no clear difference in overall survival (OS) compared with chemotherapy alone (moderate certainty).
1 finding from 1 review
Progression‐free survival · newly‐diagnosed EOC
It is very uncertain whether chemotherapy with bevacizumab followed by maintenance bevacizumab changes progression‐free survival (PFS) compared with chemotherapy alone (very low certainty).
1 finding from 1 review
Progression‐free survival · platinum‐sensitive recurrent EOC
Chemotherapy with bevacizumab followed by bevacizumab maintenance probably leads to lower progression‐free survival (PFS) compared with chemotherapy alone (moderate certainty).
1 finding from 1 review
QoL · platinum‐sensitive recurrent EOC
1 finding from 1 review
Adverse events (grade ≥ 3) · platinum‐sensitive recurrent EOC
Chemotherapy with bevacizumab followed by bevacizumab maintenance leads to higher any adverse event (grade ≥3) compared with chemotherapy alone (high certainty).
1 finding from 1 review
Hypertension (grade ≥ 2) · platinum‐sensitive recurrent EOC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Bowel fistula / perforation (grade ≥ 3) · platinum‐sensitive recurrent EOC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
QoL · newly‐diagnosed EOC
1 finding from 1 review
Adverse events (grade ≥ 3) · newly‐diagnosed EOC
Chemotherapy with bevacizumab followed by maintenance bevacizumab probably leads to higher any adverse event grade ≥ 3 compared with chemotherapy alone (moderate certainty).
1 finding from 1 review